Table 1.

Patient demographics and preoperative laboratory analysis before and after propensity score matching.

	Before matching			After matching
Factor	Control Group(n = 240)	Tα1 Group(n = 228)	P	Control Group(n = 100)	Tα1 Group(n = 100)	P
Basic characteristics
Age, yr	52.8 ± 11.7	49.7 ± 13.2	<0.001	52.8 ± 11.7	39.6 ± 11.0	.160
Gender (male/female), n	157/83	190/38	<0.001	79/21	80/20	.861
Total Bilirubin, umol/L	15.4 ± 5.9	16.6 ± 6.6	0.036	16.3 ± 6.4	16.5 ± 7.2	.858
ALT, IU/L	38.0 ± 22.1	48.5 ± 33.7	<0.001	42.9 ± 26.7.7	47.1 ± 43.2	.413
Albumin, g/L	41.9 ± 5.5	41.5 ± 4.4	0.373	41.5 ± 4.7	41.3 ± 4.2	.693
Platelet count, 109/L	109.6 ± 63.7	106.7 ± 62.6	0.620	114.6 ± 76.9	107.6 ± 59.6	.476
PT, s	12.6 ± 5.0	12.5 ± 6.0	0.888	12.4 ± 2.4	13.0 ± 7.0	.393
Neutrophil count, 109/L	3.93 ± 9.4	4.14 ± 11.3	0.824	4.74 ± 14.2	4.13 ± 13.6	.758
Lymphocyte count, 109/L	2.06 ± 8.5	2.68 ± 11.4	0.505	2.86 ± 13.1	2.81 ± 13.7	.979
Creatinin, umol/L	73.8 ± 16.1	73.5 ± 17.1	0.843	72.8 ± 14.5	72.8 ± 16.2	.993
Virologic characteristics
HbeAg (Positive/Negative), n	37/203	31/197	0.577	17/83	13/87	.428
HBV-DNA (<2 × 103/≥2 × 103), n, IU/mL	134/106	118/110	0.376	58/42	54/46	.569
Antiviral Therapy (ADV/TDF/ETV), n	124/5/111	112/12/108	0.182	60/2/38	52/0/48	.154
Tumor characteristics
Tumor size, cm	4.04 ± 3.85	3.65 ± 2.32	<0.001	4.62 ± 3.2	3.68 ± 2.3	.067
MVI (Yes vs No), n	29/211	56/172	<0.001	15/85	18/82	.568
Differentiation (Low/Moderate/High), n	89/142/9	76/146/6	0.503	37/61/2	39/60/1	.821
Cirrhosis (Yes vs No), n	149/91	186/42	<0.001	79/21	79/21	1.000
AFP (<400/≥400), n, ng/mL	174/66	156/72	0.331	65/35	64/36	.883
Operation data
Hospital stay, d	7.25 ± 1.52	8.82 ± 2.23	0.087	8.77 ± 3.17	8.13.25 ± 5.52	.795
Transfusion (Yes vs No), n	26/214	27/201	0.731	13/87	14/86	.836
Complication (Yes vs No), n	31/240	20/228	0.150	9/91	7/93	.602